{"issuance_frequency":"","notes_translated":{"fr":"Dans le but de prévenir les erreurs de médicaments, fournir aux titulaires d'une autorisation de mise en marché des renseignements sur le processus à suivre et sur l'information à soumettre à Santé Canada relativement au risque qu'un nom proposé induise en erreur ou soit confondu avec celui d'un autre produit dont l'utilisation est autorisée au Canada.","en":"To provide market authorization holders direction on the process to be followed and information to be submitted to Health Canada regarding the potential for a proposed name to be misleading or confused with another product authorized for use in Canada with the aim of preventing medication errors."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"cc05fc59-b643-40e2-9a29-e9809eebb894","metadata_created":"2021-07-07T16:51:56.312778","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-07-07T16:51:56.312785","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-07-07","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["Document d'orientation pour l'industrie","examen des noms de marque de médicaments","autorisation de mise en marché","nom proposé trompeur","confondu avec un autre produit","autorisé pour utilisation","prévention des erreurs de médication"],"en":["Guidance document for industry","review of drug brand names","market authorization","a proposed name to be misleading","confused with another product","authorized for use","preventing medication errors"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice à intention de l'industrie - Examen des marques nominatives de médicament","en":"Guidance Document for Industry - Review of Drug Brand Names"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"cc05fc59-b643-40e2-9a29-e9809eebb894","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"aa721846-fdbe-4956-8fe6-396f31668839","related_relationship":"","name_translated":{"fr":"Ligne directrice à intention de l'industrie - Examen des marques nominatives de médicament","en":"Guidance Document for Industry - Review of Drug Brand Names"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document for Industry - Review of Drug Brand Names","language":["en"],"created":"2021-07-07T16:51:56.394670","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/guidance-document-industry-review-drug-brand-names.html#a1","last_modified":null,"position":0,"revision_id":"5be8fc63-121c-4b2c-a4ee-6712813d94ac","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"cc05fc59-b643-40e2-9a29-e9809eebb894","datastore_contains_all_records_of_source_file":false,"datastore_active":false,"character_set":"","related_type":"","state":"active","id":"b0e4e106-dfb6-4e59-afe4-05503b903643","related_relationship":"","name_translated":{"fr":"Ligne directrice à intention de l'industrie - Examen des marques nominatives de médicament","en":"Guidance Document for Industry - Review of Drug Brand Names"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document for Industry - Review of Drug Brand Names","language":["fr"],"created":"2021-07-07T16:51:56.394677","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/rapports-publications/medeffet-canada/ligne-directrice-intention-industrie-examen-marques-nominatives-medicament.html#a","last_modified":null,"position":1,"revision_id":"5be8fc63-121c-4b2c-a4ee-6712813d94ac","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2014-10-22 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"cc05fc59-b643-40e2-9a29-e9809eebb894","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"To provide market authorization holders direction on the process to be followed and information to be submitted to Health Canada regarding the potential for a proposed name to be misleading or confused with another product authorized for use in Canada with the aim of preventing medication errors.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document for Industry - Review of Drug Brand Names","revision_id":"5be8fc63-121c-4b2c-a4ee-6712813d94ac"}